• Vaccine Ontology ID: VO_0004410
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Rat
• Collagen type II gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3 expressed chicken type II collagen (CCOL2A1) (Song et al., 2009).
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3 (Song et al., 2009)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004407
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Rat
• hsp65 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3 expressed mycobacterial heat shock protein 65 (hsp65) (Ragno et al., 1997).
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3 (Ragno et al., 1997)
• Immunization Route: Intramuscular injection (i.m.)

Rat Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: CD4+CD25+Treg cells play a role in restraining auto-aggressive T cells in experimental settings, and 200 μg/kg of pcDNA-CCOL2A1vaccine increased the proportion of CD4+CD25+Treg cells in the blood of arthritic rats compared with those in all other groups (Song et al., 2009).
• Efficacy: Comparison of all treated and control groups demonstrated clearly that 200 μg/kg of pcDNA-CCOL2A1 vaccine alone in a single intravenous treatment significantly reduced the severity of disease, footpad swelling, arthritic incidence, clinical scores, and deferred the onset of disease (Song et al., 2009).
• Host IgG (partial) response
  • Description: pcDNA-CCOL2A1 vaccine significantly reduced the levels of serum anti-CII IgG antibodies compared to the negative control group (P < 0.05) (Song et al., 2009).
  • Detailed Gene Information: Click Here.
• Host Il10 from Rattus norvegicus response
  • Description: Concentrations of the Th2-cytokine IL-10 in 200 μg/kg of pcDNA-CCOL2A1 vaccine group were significantly higher than those in all other groups, including the MTX positive control group (P < 0.05) (Song et al., 2009).
  • Detailed Gene Information: Click Here.
• Host TGF-B from Rattus norvegicus response
  • Description: Concentrations of the Th3-cytokine TGF-β in 200 μg/kg of pcDNA-CCOL2A1 vaccine group were significantly higher than those in all other groups, including the MTX positive control group (P < 0.05) (Song et al., 2009).
  • Detailed Gene Information: Click Here.
• Host TNF-alpha from Rattus norvegicus response
  • Description: Concentrations of the Th1-cytokine TNF-α in both 200 μg/kg of pcDNA-CCOL2A1 vaccine and MTX groups were significantly lower than those in the negative control and other treatment groups (P < 0.05). Of note, the level of TNF-α in 200 μg/kg of pcDNA-CCOL2A1 vaccine group recovered to that of the normal group (Song et al., 2009).
  • Detailed Gene Information: Click Here.

Rat Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Rats treated with pCMV3.65 showed a significantly elevated antibody levels (median 0.707) when compared with vector-treated rats (median 0.351; P < 0.01) and with naive animals (median 0.0715; P < 0.01). Similarly, spleen cells from pCMV3.65-treated rats exhibited significantly higher proliferative responses against the mycobacterial recombinant antigen when compared with vector treated animals (P < 0.05) or with naive rats (P < 0.01) (Ragno et al., 1997).
• Efficacy: The pCMV3.65-treated rats were significantly protected from disease development in comparison with the control groups injected with the empty plasmid (Ragno et al., 1997).